Literature DB >> 15491711

Characterization of minute adenocarcinomas of prostate at radical prostatectomy.

Alexander M Truskinovsky1, Harriete Sanderson, Jonathan I Epstein.   

Abstract

OBJECTIVES: To characterize minute prostate cancer seen at radical prostatectomy. With aggressive screening and more extensive biopsy sampling, we have increasingly seen these cancers at radical prostatectomy.
METHODS: We examined radical prostatectomy specimens submitted in total for minute cancer.
RESULTS: During the past 1.5 years, 78 prostates (5.2%) had either no cancer (2 cases) or contained between one and six foci of organ-confined carcinoma (76 cases) measuring 6 mm or less, with a Gleason score of 6 or less. The mean prebiopsy serum prostate-specific antigen level was 5.8 ng/mL, and 84.6% of the patients had undergone biopsy because of an elevated prostate-specific antigen level. Of these patients, 40% had had either benign or atypical diagnoses on prior biopsies, and 43% had only minute (0.5 mm or less) foci of carcinoma on biopsy. The radical prostatectomy specimens had a mean of two cancer foci measuring, on average, 3 mm in the greatest dimension. In 85% of the cases, the side of the positive biopsy matched the side of the carcinoma found at radical prostatectomy; 81.5% of cases had high-grade prostatic intraepithelial neoplasia immediately adjacent to the cancer.
CONCLUSIONS: The incidence of minute carcinoma of the prostate has increased from 0.5% in 1988 to 5.2% in the current study. The patients often had moderately increased prostate-specific antigen levels and minute foci of carcinoma on biopsy. These small tumors at radical prostatectomy are usually discovered by fortuitous biopsy that is often preceded by other biopsies with noncancerous diagnoses. Patients with the above clinical and biopsy findings should be counseled about the possibility of finding only minute foci of carcinoma at radical prostatectomy and may want to consider watchful waiting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15491711     DOI: 10.1016/j.urology.2004.05.026

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

Review 1.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

2.  Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.

Authors:  Ghil Suk Yoon; Wenle Wang; Adeboye O Osunkoya; Zhaoli Lane; Alan W Partin; Jonathan I Epstein
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

3.  TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma.

Authors:  Roula Albadine; Mathieu Latour; Antoun Toubaji; Michael Haffner; William B Isaacs; Elizabeth A Platz; Alan K Meeker; Angelo M Demarzo; Jonathan I Epstein; George J Netto
Journal:  Mod Pathol       Date:  2009-09-04       Impact factor: 7.842

4.  Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.

Authors:  Roberta Mazzucchelli; Francesca Barbisan; Adriano Tagliabracci; Antonio Lopez-Beltran; Liang Cheng; Marina Scarpelli; Rodolfo Montironi
Journal:  Virchows Arch       Date:  2007-02-07       Impact factor: 4.064

Review 5.  Nondetectable Prostate Carcinoma (pT0) after Radical Prostatectomy: A Narrative Review.

Authors:  Nikolaos Kalampokis; Nikolaos Grivas; Markos Karavitakis; Ioannis Leotsakos; Ioannis Katafigiotis; Marcio Covas Moschovas; Henk van der Poel
Journal:  Curr Oncol       Date:  2022-02-23       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.